**In the Claims:**

Please cancel claims 1-60.

Please add the following new claims 61-96.

61. (New) An aerosol formulation consisting essentially of the components:
    A. an effective amount of albuterol or a salt thereof;
    B. 1,1,1,2-tetrafluoroethane; and
    C. optionally, one or more components selected from one or more of preservatives, buffers, antioxidants, sweeteners and taste masking agents; and wherein said formulation is free of surfactant and free of excipient.

62. (New) The formulation of claim 61 containing 0.01 to 1 percent by weight albuterol or a salt thereof.

63. (New) The formulations of claim 61 containing 0.03 to 0.7 percent by weight albuterol or a salt thereof.

64. (New) The formulations of claim 61 containing 0.05 to 0.5 percent by weight albuterol or a salt thereof.

65. (New) The formulation of claim 61 wherein said albuterol or a salt thereof is a powder having a mean particle size of 1 to 5 microns.

66. (New) The formulation of claim 61 wherein component A is selected from the group consisting of albuterol and albuterol sulfate.

67. (New) An aerosol formulation prepared by combining components consisting essentially of:

    a. an effective amount of albuterol or a salt thereof;
    b. 1,1,1,2-tetrafluoroethane; and
    c. optionally, one or more components selected from one or more of preservatives, buffers, antioxidants, sweeteners and taste masking agents; and wherein said formulation is free of surfactant and free of excipient.

68. (New) The formulation of claim 67 wherein component A is selected from the group consisting of albuterol and albuterol sulfate.

69. (New) The formulation of claim 61 or claim 67 which is contained in a metered dose inhaler.

70. (New) A method of treating asthma comprising administering to a mammal by inhalation a treatment-effective amount of an aerosol formulation prepared by combining components consisting essentially of:

a. an effective amount of albuterol or a salt thereof;
b. 1,1,1,2-tetrafluoroethane; and
c. optionally, on or more components selected from one or more of preservatives, buffers, antioxidants, sweeteners and taste masking agents; and wherein said formulation is free of surfactant and free of excipient.

71. (New) The method of claim 70 wherein the formulation is contained in a metered dose inhaler.

72. (New) An aerosol formulation consisting of the components:

a. an effective amount of albuterol or a salt thereof;
b. 1,1,1,2-tetrafluoroethane; and
c. one or more components selected from one or more of preservatives, buffers, antioxidants, sweeteners and taste masking agents.

73. (New) An aerosol formulation consisting of the components:

a. an effective amount of albuterol or a salt thereof; and
b. 1,1,1,2-tetrafluoroethane; and

74. (New) An aerosol formulation consisting essentially of the components:
a. an effective amount of albuterol or a salt thereof; and
b. 1,1,1,2-tetrafluoroethane; and
wherein said formulation is free of surfactant and free of exipient.

75. (New) An aerosol formulation prepared by combining components consisting of:

a. an effective amount of albuterol or a salt thereof;
b. 1,1,1,2-tetrafluoroethane; and
c. one or more components selected from one or more of preservatives, buffers, antioxidants, sweeteners and taste masking agents.

76. (New) An aerosol formulation prepared by combining components consisting of:
a. an effective amount of albuterol or a salt thereof; and
b. 1,1,1,2-tetrafluoroethane.

77. (New) An aerosol formulation prepared by combining components consisting essentially of:

a. an effective amount of albuterol or a salt thereof; and
b. 1,1,1,2-tetrafluoroethane; and
wherein said formulation is free of surfactant and free of excipient.

78. (New) The formulation of any one of claims 72-77 containing 0.01 to 1 percent by weight albuterol or a salt thereof.

79. (New) The formulation of any one of claims 72-77 containing 0.03 to 0.7 percent by weight albuterol or a salt thereof.

80. (New) The formulation of any one of claims 72-77 containing 0.05 to 0.5 percent by weight albuterol or a salt thereof.

81. (New) The formulation of any one of claims 72-77 wherein said albuterol or a salt thereof is a powder having a mean particle size of 1 to 5 microns.

82. (New) The formulation of any one of claims 72-77 wherein component A is selected from the group consisting of albuterol and albuterol sulfate.

83. (New) The formulation of any one of claims 72-77 which is contained in a metered dose inhaler.

84. (New) A method of treating asthma comprising administering to a mammal by inhalation a treatment effective amount of an aerosol formulation prepared by combining components consisting of:

    a. an effective amount of albuterol or a salt thereof;
    b. 1,1,1,2-tetrafluoroethane; and
    c. one or more components selected from one or more of preservatives, buffers, antioxidants, sweeteners and taste masking agents.

85. (New) A method of treating asthma comprising administering to a mammal by inhalation a treatment effective amount of an aerosol formulation prepared by combining components consisting of:

    a. an effective amount of albuterol or a salt thereof; and
    b. 1,1,1,2-tetrafluoroethane.

86. (New) A method of treating asthma comprising administering to a mammal by inhalation a treatment effective amount of an aerosol formulation prepared by combining components consisting essentially of:
    a. an effective amount of albuterol or a salt thereof; and
    b. 1,1,1,2-tetrafluoroethane; and
    wherein said formulation is free of surfactant and free of excipient.

87. (New) The method of any one of claims 84-86 wherein the formulation is contained in a metered dose inhaler.

88. (New) An aerosol formulation comprising:

a. an effective amount of mometasone furoate;
b. 1,1,1,2-tetrafluoroethane; and
c. optionally, one or more components selected from at least one of the following:
excipients;
surfactants; and
additives which are;
preservatives;
buffers;
antioxidants;
sweeteners; and
taste masking agents.

89. (New) The formulation of claim 88 containing 0.01 to 1 percent by weight medicament.

90. (New) The formulation of claim 88 containing 0.03 to 0.7 percent by weight medicament.

91. (New) The formulation of claim 88 containing 0.05 to 0.5 percent by weight medicament.

92. (New) The formulation of claim 88 wherein the medicament is a powder having a men particle size of 1 to 5 microns.

93. (New) The formulation of claim 88 which is substantially free of chlorofluorocarbons.

94. (New) The formulation of claim 88 containing the following:

| Component | Weight Percent |
|---|---|
| Mometasone furoate | 0.01-1 |
| 1,1,1,2-Tetrafluoroethane | 25-99.99 |
| Excipient | 0-75 |
| Surfactant | 0-3 |

95. (New) The formulation of claim 88 containing the following:

| Component | Weight Percent |
|---|---|
| Mometasone furoate | 0.03-0.7 |
| 1,1,1,2-Tetrafluoroethane | 50-99.97 |
| Excipient | 0-50 |
| Surfactant | 0-2 |

96. (New) The formulation of claim 88 containing the following:

| Component | Weight Percent |
|---|---|
| Mometasone furoate | 0.05-0.5 |
| 1,1,1,2-Tetrafluoroethane | 50-99.95 |
| Excipient | 0-50 |
| Surfactant | 0-1 |